Classes of drugs that target the cellular components of inflammation under clinical development for COPD.
Maria Gabriella MateraLuigino CalzettaRosa AnnibaleFrancesco RussoMario CazzolaPublished in: Expert review of clinical pharmacology (2021)
Although the results of many clinical trials with new molecules have often been disappointing, several studies are underway to investigate whether some of these molecules may be effective in treating specific subgroups of COPD patients. Indeed, the current perspective is to apply a more personalized treatment to the patient. This means being able to better define the patient's inflammatory state and treat it in a targeted manner. Unfortunately, the difficulty in translating encouraging experimental data into human clinical trials, the redundancy in the effects induced by signal-transmitting substances and the nonspecific effects of many classes that are undergoing clinical trials, do not yet allow specific inflammatory cell types to be targeted.
Keyphrases
- clinical trial
- oxidative stress
- chronic obstructive pulmonary disease
- end stage renal disease
- case report
- phase ii
- lung function
- endothelial cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cancer therapy
- prognostic factors
- single cell
- electronic health record
- stem cells
- phase iii
- cell therapy
- drinking water
- randomized controlled trial
- induced pluripotent stem cells
- patient reported outcomes
- mesenchymal stem cells